Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia
Status:
Terminated
Trial end date:
2021-02-23
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of buspirone in combination
with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson's
disease (PD).